Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer

NCT ID NCT06026657

Recruiting now Disease control Sponsor: Margaret Gatti-Mays Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial is testing whether combining an antibody called naxitamab, the chemotherapy drug gemcitabine, and specially engineered natural killer (NK) cells from a healthy donor can safely shrink tumors in people with advanced HER2-negative breast cancer that has spread. The cancer must express a marker called GD2, which is common in certain aggressive subtypes. The study aims to find the best dose and evaluate how well the immune system can be directed to attack the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of naxitamab (an antibody targeting GD2), gemcitabine (chemotherapy), and engineered natural killer (NK) cells from a universal donor
What this could lead to
If successful, this approach could offer a new treatment option for people with advanced HER2-negative breast cancers that express GD2, a type of cancer that currently has limited therapies.
What could go wrong
This is an early-phase trial (1b/2) with a small number of participants, so safety and effectiveness are still unknown. The combination therapy may cause significant side effects, including immune reactions or toxicity from chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANATOMIC STAGE IV BREAST CANCER AJCC V8 HER2-NEGATIVE BREAST CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.